Novel sirna-nanoparticle platform for treating drug-resistant HER2 positive breast cancer

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201300078C
Awardee
Awarding agency
Obligated
$1,200,000

Award facts

Opportunity
Contract value 100% obligated
$1,199,999.96 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541990 All Other Professional, Scientific, and Technical Services
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 24 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Lake Oswego, OR 97035, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 6 · Purpose of this modification is to DE-obligate the remaining funds. -$0
Other Administrative Action 5 · Sbir phase II topic 313: novel sirna-nanoparticle platform for treating drug-resistant HER2 positive breast cancer $0
Other Administrative Action 4 $0
Supplemental Agreement for work within scope 3 $0
Exercise an Option 2 $1,000,000
Other Administrative Action 1 $0
Original award $200,000

Quick answers

Who was awarded contract HHSN261201300078C?

HHSN261201300078C was awarded to PDX Pharmaceuticals Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2013.

How much is contract HHSN261201300078C worth?

The government has obligated $1,200,000 on HHSN261201300078C.

Was contract HHSN261201300078C competed?

The extent of competition for HHSN261201300078C was full and open competition after exclusion of sources. The government received 24 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award